Hoping to win where Novartis failed, Inhibrx files for $75M IPO by Nick Paul Taylor Tuesday, June 4, 2019 The Celgene-partnered single-domain antibody specialist will use the cash to complete phase 1 trials of three oncology and rare disease drugs.
Confo raises €30M series A round to target hard-to-drug GPCRs by Nick Paul Taylor Tuesday, May 7, 2019 The series A round sets Confo up to advance drugs derived from a novel way of stabilizing GPCRs and performing more sensitive screens.
Chimerix CEO replaced by a trio of officers—Chutes & Ladders by Conor Hale Friday, February 8, 2019 Chimerix’s CEO replaced by a trio of officers; Decibel hires new CMO; and Kiadis poaches Ablynx’s CSO.
A universal flu vaccine from llamas? by Angus Liu Monday, November 5, 2018 Using broadly neutralizing single-domain antibodies from llamas, scientists have designed a vaccine that can potentially combat almost all flu viruses.
Robert Zeldin to take post at Acceleron as its CMO retires by Conor Hale Friday, July 6, 2018 Ablynx CMO Robert Zeldin is moving to Acceleron, to take over for longtime CMO Matthew Sherman, as it begins to get phase 3 data on luspatercept.
Chutes & Ladders—Millennium's Dunsire named CEO of Lundbeck by Conor Hale Friday, July 6, 2018 Ex-Millennium chief named CEO of Lundbeck; Ablynx's CMO to take post at Acceleron; and PredictImmune appoints new CEO.
GI toxicity hits midstage Sanofi GLP-1 drug as patients drop out by Ben Adams Friday, April 27, 2018 Sanofi says its GLP-1 drug SAR425899 is undertaking new tests to try to get around dosing issues that is causing GI problems.
Novo moves into sickle cell with $400M EpiDestiny deal by Nick Paul Taylor Friday, April 6, 2018 The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.
As Sanofi buyout nears, Ablynx lupus drug flunks midphase trial by Nick Paul Taylor Monday, March 26, 2018 The setback tarnishes one of the drugs Sanofi is set to acquire through its €3.9 billion takeover of Ablynx.
Special Report—Biotech IPOs rebounded in 2017 and may keep rolling into 2018 by Amirah Al Idrus 2017 was "good, but not great" for biotech IPOs, yet insider buying was still high at 34%.
